expand

The Feinstein Institute for Medical Research

Empowering Imagination. Pioneering Discovery.
Print | Font Size ( + ) ( - ) | Bookmark | Email

John M. Kane, MD

Investigator, Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research

Vice President, Behavioral Health Services, North Shore-LIJ Health System

Chairman, Department of Psychiatry, The Zucker Hillside Hospital

Chair & Professor, Psychiatry and Professor of Molecular Medicine,
Hofstra North Shore-LIJ School of Medicine

Phone: (718) 470-8141
Email: psychiatry@nshs.edu

About the Investigator

John M. Kane, MD, is vice president for Behavioral Health Services of North Shore-LIJ Health System and chairman of psychiatry at The Zucker Hillside Hospital. He is chairman of psychiatry and professor of psychiatry and molecular medicine at the Hofstra North Shore-LIJ School of Medicine. Dr. Kane received his BA from Cornell University and his MD from the New York University School of Medicine.

He currently directs the NIMH-funded Advanced Center for Interventions and Services Research in Schizophrenia at The Zucker Hillside Hospital. He has been a member of the Board of Scientific Counselors for NIMH, and he has served on the council of the American College of Neuropsychopharmacology. He has chaired the NIMH Psychopathology and Psychobiology Review Committee as well as the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration.

Dr. Kane is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Association Foundations’ Fund Prize for Research, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.

Research Focus

Dr. Kane is a schizophrenia researcher with extensive experience in intervention and services research. He has been very involved in developing live two-way video for use in research in patients with schizophrenia. He has also been working on the development of new strategies for patient engagement, adherence monitoring, and clinical decision making using advanced technologies.

He directs an NIMH-funded Advanced Center for Services and Interventions Research that has provided an infrastructure for many of these efforts. His clinical program and health system are committed to implementing new technologies that can enhance access, quality of care and outcomes while increasing cost effectiveness. He is eager to conduct this research in order to further inform our efforts in both a Health Home and Behavioral Health Organization, which are part of the health system. He will be working closely with the New York State Office of Mental Health to ensure feasibility and sustainability of new models of technology-enhanced care.

For over 30 years, Dr. Kane has been an international leader in the field of schizophrenia research. His work has focused on improving the early diagnosis and treatment of this illness, as well as developing new treatments and treatment strategies to improve its long-term course and outcome. He was a pioneer in the study of first episode schizophrenia and also conducted groundbreaking work with clozapine for treatment resistant schizophrenia. He has continuously focused on both therapeutic and adverse effects of psychotropic drugs, thereby informing benefit-to-risk considerations. Dr. Kane has always been on the forefront of bringing the next generation of medicines to patients in order to enhance long-term effectiveness and quality of life.

The laboratory runs a number of large clinical trials. Dr. Kane also devotes his efforts to standardizing the outcome measurements in psychiatric research and helping to ensure the translation of research into clinical practice. Since the beginning of his residency at The Zucker Hillside Hospital in Glen Oaks in 1971, Dr. Kane has committed his career to unraveling the mysteries of this brain disorder.

The program, under his direction, continues to conduct pioneering studies on the treatment of first episode schizophrenia. In addition, he and his team are studying the use of new technologies – from smartphones to two-way video – to enhance disease management. Dr. Kane and his colleagues have helped to determine treatment strategies for all phases and subtypes of schizophrenia. His findings have been circulated worldwide and have become part of the fabric of modern care. All of the scientists within the Center work in collaboration with Dr. Kane on the clinical pharmacology studies underway at The Zucker Hillside Hospital. He is the principal investigator on three large federal grants.

Scientific Investigators/Collaborators:
Christoph Correll, MD
Juan Gallego, MD
Vivian Kafantaris, MD
Taishiro Kishimoto, MD, PhD
Anil Malhotra, MD
Alan Mendelowitz, MD
Georgios Patrides, MD
Delbert Robinson, MD
Serge Sevy, MD

Education

Cornell University
Degree: BA
1967
Field of Study: English

NYU School of Medicine
Degree: MD
1971
Field of Study: Medicine

LIJ – Hillside Medical Center
1975
Field of Study: Psychiatric Residency

Awards & Honors

1978 Chairman, Psychopharmacology Drugs Advisory Committee, Food and Drug Administration
1981 Associate Professor of Psychiatry, School of Medicine, SUNY at Stony Brook
1984 Chairman, APA Task Force on Tardive Dyskinesia
1984 Chairman, ACNP Task Force on Clinical Research Settings
1984 Member, NIMH Psychopharmacological, Biological & Physical Treatment Review Committee
1985 Professor of Psychiatry, School of Medicine, SUNY at Stony Brook
1987 Chairman, APA Committee on Research on Psychiatric Treatment
1988 Chairman, Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center
1989 Professor of Psychiatry, Albert Einstein College of Medicine
1990 Chairman, NIMH Psychopathology & Clinical Biology Research Review Committee
1996 Professor of Neuroscience, Albert Einstein College of Medicine
1998 Chairman, Psychopharmacology Drugs Advisory Committee, Food and Drug Administration
1998 Board of Scientific Counselors, NIMH
2000 Professor of Neurology, Albert Einstein College of Medicine
2005 President, American Society of Clinical Psychopharmacology
2007 President, Schizophrenia International Research Society
2011 Professor and Chairman Department of Psychiatry, Hofstra North Shore-LIJ School of Medicine

Publications
  1. Kane JM: “Schizophrenia.” N Engl J Med 334(1):34-41, 1996.
  2. Woerner MG, Alvir JmaJ, Saltz BL, Lieberman JA, Kane JM: “Prospective study of tardive dyskinesia in the elderly: Rates and risk factors.” American Journal of Psychiatry. 155(11): 1521-1528, 1998.
  3. Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J: “Effects of clozapine on auditory event-related potentials in schizophrenia.” Biological Psychiatry. 44(8): 716-725, 1998.
  4. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. “A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.” American Journal of Psychiatry. 159(4): 554-560, 2002.
  5. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. “Relapse prevention in schizophrenia with new generation antipsychotics: A systematic review and explorative meta-analysis of randomized controlled trials.” Am J Psychiatry 160(7):1209-1222; 2003
  6. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM: “Early prediction of antipsychotic response in schizophrenia.” Am J Psychiatry 160(11):2063-5, 2003
  7. Correll CU, Leucht S, Kane JM: “Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies.” Am J Psychiatry 161(3):414-425; 2004
  8. Robinson DG. Woerner MG. Delman HM. Kane JM. “Pharmacological treatments for first-episode schizophrenia.” Schizophrenia Bulletin. 31(3):705-22, 2005
  9. Correll CU. Manu P. Olshanskiy V. Napolitano B. Kane JM. Malhotra AK. “Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.” JAMA, 302(16):1765-73, 2009 (Kane and Malhotra shared last authorship)
  10. Strom BL, Eng SM, Faich F, Reynolds RF, D’Agostino RB, Ruskin J, Kane JM. “Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).” Am J Psychiatry 2011;168:193-201.

View more at PubMed